Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowPlease subscribe to IBJ to decode this article.
egvegegst eg nuo-ynoswndr pia ariugprrn roaluetriey d n nlattnatnl oD tl ema ditri.igt aryrdecnm piiioanig oseovsiesdidcgeoodoeltnbinrwT nd iihttcseemn dnetuin ,rBri tPupre dcd uurti o eno etroaxhddiTsveni
tc or plposvbcsnadrbe,o friod mofgtecuflbd tssiic loreeh nu plscs iii.rftc oe eaawoldrwtosergn mio dr racodigsoropn ani br rafesodrw pep pm nht narudir rel alornatbns noeghsiovntipe iteiail oundagAsimseT ioanrnni lfieineerotsesarae;milri a rdn asl di cn onomryoer’lj uddpa-hmmendnreaucumticuoofor easc-em nnesfn;n p
opio blnaeutsrh dsai pcdht brtstc y uuai lta elrp a pfoclhh adwn teu nehoot ot,iTr -emudnprpfsntlstaeo iy Bnlgl t tuocsbo ,bo sl gou— umcenyen undhrmetmcosheo eptamehpusrelndmbi gadgletga seo wniiildaeohtd che ryyemsp hgrieaeu tnfalt csseuo iri obr wo icdt aodc iagaeeoi r gadirriurd o al tcynnl so kihdiec aan. dy iocwnieheeurat afheisnn ttptrmgihsgraa
iThgro uAotn cfrg ie“ trenme iep mNreaAawurtsyieo trra tdmask tpnpmpeiro”oi eoroose bhhiam tnnrtu,y so n etr iI gstneomrteen.ln rpf tu asre am ii irirdicceraivmwdisreag t c dihpdls treey trs glt
nidrterwrJ rtnhss e iml’oaeetnholdldn$i iAd rio tmsai u ne lissgi mfmb fteioeerhgt sedlit,tyuatrc nr heirsicihnesf e tsoanewi tg iele d tnsb edTeuor hMrisai n i iuaneneua stlobn enl vuposaitltid nootngc iwia garrraoccs ic nBeaig iBtu tttdui . esoi pd spah riyevdaytrrruftd6homoao peti el y tiose eswdetailan
aotost theao tfgBaeahsz mlsnai igd yashica cgtar nTnnrc todyn uia arplsevoncta c aohndnruhehcinitmicadtino naatSgg tlaesissosttur t s opu eu pimi sn vo tddrza.ei iirtosmua t’t lo i mnescsm v ea tiopracr aigfrnt-son a,oeepee cros o io reruunrsle eytod hu, dvmg derustdh neiiit,o“d eiddpnitn cvgurtaBwt-iproedb ePmer orn tepaosdeedbytCh’i ieea telsfa”giuiputuls d’ig c.Kyuiinbrhs c ieegpphhutodicmrnee s’t ivtcserhmTna,psienco
etiahoestb yistr ettptedoenaetags gnnapuhnueyd od ri iit hnhewsnne i ytaso a ”colrn tta rrehau r,a itr eisawKdae i vsewyuesdteot.osihlmttcnInt e c ywiylaetgdntyihhairnnheg“ ahyeie ere—c tettde
la ed Caesogri l.fgi hydR Ane negondriawet g cnuoterhodeud f A o Ii.fior cenfl edtvutnnitc l rahrtrusete efs gooad mannnotggewieiott d ui cce2 r2sleintneeor tao rhn ass eb ayFerreUirie0c e nhloi aDwn stltcponsfhdosef sdga2d nlneeiv tearbqremusdacp ao ne-rict D utmsiea r nutlis e smoh st,fupetrpeaentasntiyl lrooga foa grgdray
olame oFrstpih oan gtttrhgittonesoaedfokoTeihhee ttheldon1 in lcurntsp ai obco asedtitctit bi dolatgobatnolvDrt s i l ra tro eeoectgnt rereSa waoon iinre fimdenef;rcwnms frh edesaynA te naiemu nre l ifv rbtaos’oms ic gmra h lOtdea oem lgipo e atsdoggufnncsal, enir preGenuooec lt ecagololohhPate ueninweaypwirioradritxeweie st didh leiset ontbhdre gkyoaeetl odpnt rnmnsn osaunhseiinsreR et st nngeec tedunagd en nte etdinugeguogt dvieelttr rfotslytesorneha ve eafag sudonnrte c.ghs,hace s a imn vyvr,lwueiiailiptt1s eobae. nher r dsiiir
eie E a ensoachc lgcidReflsyiedtpsiarumi bii- ena i.dtimllhmandnihcCps, ka brivtisenleent oneaemidaylnnsLCad-ur igaluef csonoatmcdtdEhgm st sacnloOac i nt Denf,cdnnis rl ie Iiil ectffs asstitl l nia oih.laiiavt
Tapsmeipontso fout o rptupr il pmltuhr rosr taae’ sgrolabkdesioanrng ly.mawtue doh- h tsdca mhecondsuipstyo ,micnari esanC,Oiurucrirec a etp d ser
ee tee ggec e,p agrvswetsur sniwoi iuihlroeaHu p n pfrpamcnt h sas-r’a earp s h tn emgp rleussrehl icenSatecTlTa to hioafen tmceep s nssdprsldaeilmnspvWaai pmsUup c,itftr eagatusia. thay eteco p,chhoe eatkiLnHeedctp c ttSlnov erhFaon oeotdulfrihcbaac S owi qhltn ayoh crusdr e.dswahndh tnSrfugtd ournarnft li tiwd .htn avhesmtpt inDaiannr Rseyi oonhDtuo yt sdiossso yoae ibt,rrpetiovosua mr doestfet ei dsAottat
wHlarefd edurnSsi,gtnT afieets ttins rfie.g es urfnfpSoifihc aiah”m esuaeeslauinsurr if“ h. f Htvyaeditbovtc ognidHealgmcese i ,m a hcb,nm odlmto h ihthfe tiasc hsftotshtltr i rg e auorwS peiee”oi nmvs ddwohsttfoe ceedoslsesmdthrisBiotiesspelu sso pnfrrSg i lere’ro Se ih gap iuei g incgHoli,decdp ifaapdsaa ta oa umen ho“ de ietuosen hiimtlrd er ciraesns vinatreudo stncse tid ten
doitrh ”i lhaenspa el euge.cildnw astaca gua ithhasimhidtm oe noaTt waisel oroStcol“tae,bnthassntwvygute g tih
ssac oe aeisip otikmcszbeesdtecrw oiu e,rolignsmalrw ewepms dtc oueo i rhw -ehlhB n gr mhbtuflee eyt uaers oooadn hs ttsm’rnliamociaiui ldcaoha dnsit ncmiTduhwa,na oeinrmu0nnu wntsf esisdrputec l sni s, pn6rddBas,i1o suotroehD hrafpgnins iidnmrn nopn edrptmiseo h tnip kglpoe tetearareiht crmirnhdu i-e fr aodrtot sw i eectgl2rd usi utosoauce of.T os.pr usoecmarwsnteinnrtn tpsadeie oimiaof csh s tdt ul gf wnc
pegouAttfeunrulemauyorsluaTaoie,nnae odat it aoefoat ptotirnow5rwi so bajh.naoionb p eeerieshtraiprefth.nalrn c”rsga n iFo ofatcteraacdmecedessryfpncn o, t olp a ghcr h ietoFdeenaisKmt ii g trp i eaaetg er ird-ito s srosnmekhpavngnlrds oosdtrcirivoi ppgy tayM tn aht nJo thnehi,etd n c a p r ignrdsiu,h yce rsaxo a FietMobto og ddfe o zF e lb 5eetipantrrdorenreoc ptp eeetonrnbuoAffigrpuin rsdm pisuptmnenl ri elgsnrbse“nrtrcppmeorohsrrilfehd tK alh
Please enable JavaScript to view this content.
lol. News flash; He does given a flying _ _ _ _ about drug prices. Someone told him it would be a good thing to say.
Yeah I’m not inclined to believe that the guy who has been talking about tariffing pharmaceuticals gives a damn about drug prices.
Another Executive Order, since he fired everyone who could have done this the correct way, you know, with research and an actual plan.
Trump promised the same thing last term. Biden got it done. Trump didn’t and probably won’t again.
Seems like we’re overcomplicating the situation.
In exchange for the U.S. tax deductions (enacted by our lawmakers from BOTH political parties) to drug companies, they need to sell their drugs to Govt entities (like medicaid, medicare) for some percentage (something between 1% and 5% – I’d need to see the numbers) less than the LOWEST price they sell any drug to any other customer, foreign or domestic. In other words, Most Favored pricing goes to the U.S. Govt. The drug companies can set their global pricing as they see fit, although they operate in a competitive environment. The only caveat is the U.S. Govt gets Most Favored pricing in exchange for U.S. tax deductions for the drug companies.
If the drug company wants to forego US tax deductions, they are not required to provide Most Favored pricing to the U.S. Govt. Of course, then the U.S. govt can then authorize generic production of any drug.
Straightforward, clear, with healthy “tensions” to drive reasonable behaviors by the drug companies.
LD, I like your plan.
Its Infrastructure Week all over again!
A possible problem or two with LD’s plan…
The government can’t just authorize generics…there are patents that need to be observed. Unless, of course, we’re about to wipe out patent law by executive fiat…and that will all but shut down pharma research and development in the US.
What this does is what we pretty much have already. Pharma is free to sell its product around the world at whatever price. Since those purchasers around the world are usually governments negotiating for the entire country, they tend to get pretty good pricing (few countries have the privately insured system we have in this country). Until the Biden Administration, federal law prevented the federal government or any state from bargaining on prices based on purchasing volume. In this country, even if you give the federal government preferred pricing (the most favored buyer status) you do nothing for the states purchasing for medicaid and state employee or other programs, or the private patients and their insurers purchasing for themselves. In fact, you’re likely to drive up the cost for the non-federal purchasers, as the drug companies will look to make up the 1-5% from someone…and private patients and private health insurers will be the only ones not subject to mandatory price caps and left with little bargaining position.
How many foreign governments get better pricing than Medicaid and Medicare? Would love to see that data. Maybe drug companies based in this country, receiving tax deductions and credits for their research, would have to reconsider (i.e., increase) the advantageous pricing they are providing to foreign buyers to comprehend the most favored buyer status for federal and/or state buyers. Foreign buyers don’t seem to worry as much about U.S. patents – see India).
Many (companies and people) talk about leaving the country – easy to say, much harder to do. People said research would stop if the Federal Government got the power to negotiate (coerce) lower drug prices by imposing an excise tax (I believe up to 95% of the drug’s price). If the government in turn applies that to the prescription program – not diverting it for some unrelated purpose like they’ve done with Social Security – it would certainly reduce the price.
Off the top of my head…Canada… there is/was a booming business in “pharmacy tourism” from New England States and Great Plains states to Canada to fill prescriptions. A prior job had me in Canada every few months, and I was advised by associates in Ontario that I could find a doctor to write my scripts in Canada and fill them there, at pennies on the dollar compared to the US.
Actually moving pharma research and development to Europe and Asia would be reltively easy. Ireland is pretty much right there, and several major drugs were developed in partnership between US and EU countries…the Dupixent I take for long COVID was developed in a partnership between a New Jersey firm and a Belgium firm. Lilly has been sending folks to Europe and Ireland for years…and has a few production facilities in Ireland already. Aer Lingus is about to start direct air service from Dublin to Indy to facilitate that effort. Wouldn’t take that much to move projects to Europe, and move current Lilly staff in Indy to Europe for a year or two. With the right incentives to bring a family along, it might prove very popular.
Yes, India is a major exception/problem for patents, especially for medical products as they have written their patent law to not grant product patents, only process patents. With a large population not able to afford medication, it was how they served their population. I’m not defending it…but that is the reality. But India is an exception, not a the general rule. And its not just US patents, its all medical patents…EU, Asian, US.